

Rajeev Vibhakar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5243272/publications.pdf>

Version: 2024-02-01

139
papers

5,924
citations

101543

36
h-index

76900

74
g-index

144
all docs

144
docs citations

144
times ranked

8258
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
2	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
3	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
4	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
5	Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2008, 90, 1-7.	2.9	230
6	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	7.7	169
7	MicroRNA 128a Increases Intracellular ROS Level by Targeting Bmi-1 and Inhibits Medulloblastoma Cancer Cell Growth by Promoting Senescence. <i>PLoS ONE</i> , 2010, 5, e10748.	2.5	158
8	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
9	Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 6665-6674.	0.9	135
10	Activation-Induced Expression of Human Programmed Death-1 Gene in T-Lymphocytes. <i>Experimental Cell Research</i> , 1997, 232, 25-28.	2.6	133
11	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	27.8	129
12	Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. <i>ELife</i> , 2017, 6, .	6.0	128
13	Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. <i>Neuro-Oncology</i> , 2013, 15, 149-160.	1.2	115
14	Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. <i>Oncotarget</i> , 2014, 5, 2355-2371.	1.8	103
15	B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2013, 111, 257-264.	2.9	101
16	MicroRNA 218 Acts as a Tumor Suppressor by Targeting Multiple Cancer Phenotype-associated Genes in Medulloblastoma. <i>Journal of Biological Chemistry</i> , 2013, 288, 1918-1928.	3.4	100
17	The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. <i>Gene</i> , 1997, 197, 177-187.	2.2	99
18	Survey of MicroRNA expression in pediatric brain tumors. <i>Pediatric Blood and Cancer</i> , 2011, 56, 211-216.	1.5	89

#	ARTICLE	IF	CITATIONS
19	scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. <i>Nature Communications</i> , 2019, 10, 5829.	12.8	77
20	Targeting the enhancer of zeste homologue 2 in medulloblastoma. <i>International Journal of Cancer</i> , 2012, 131, 1800-1809.	5.1	71
21	Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. <i>BMC Cancer</i> , 2012, 12, 80.	2.6	69
22	Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. <i>Neuro-Oncology</i> , 2007, 9, 135-144.	1.2	64
23	Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. <i>Molecular Cancer</i> , 2014, 13, 72.	19.2	62
24	Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. <i>Cancer Immunology Research</i> , 2015, 3, 1165-1174.	3.4	61
25	A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2058-2068.	4.1	61
26	Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. <i>Journal of Neuro-Oncology</i> , 2013, 111, 113-121.	2.9	59
27	Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. <i>Journal of Neuro-Oncology</i> , 2012, 107, 517-526.	2.9	56
28	High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. <i>Neuro-Oncology</i> , 2011, 13, 1296-1307.	1.2	52
29	Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, 273-286.	1.2	52
30	Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. <i>Neuro-Oncology</i> , 2012, 14, 175-183.	1.2	51
31	Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. <i>Oncotarget</i> , 2018, 9, 13894-13910.	1.8	47
32	Single-Cell RNA Sequencing of Childhood Ependymoma Reveals Neoplastic Cell Subpopulations That Impact Molecular Classification and Etiology. <i>Cell Reports</i> , 2020, 32, 108023.	6.4	47
33	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47
34	Fractionated stereotactic radiosurgery for recurrent ependymoma in children. <i>Journal of Neuro-Oncology</i> , 2014, 116, 107-111.	2.9	45
35	Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo. <i>International Journal of Cancer</i> , 2019, 144, 1983-1995.	5.1	43
36	A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. <i>ACS Chemical Biology</i> , 2016, 11, 921-930.	3.4	42

#	ARTICLE	IF	CITATIONS
37	Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1095-1102.	1.5	40
38	Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines. <i>Pediatric Blood and Cancer</i> , 2010, 55, 35-41.	1.5	39
39	Aurora kinase A as a rational target for therapy in glioblastoma. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 6, 98-105.	1.3	39
40	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. <i>Cell Reports</i> , 2020, 33, 108286.	6.4	39
41	MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3). <i>Brain Pathology</i> , 2020, 30, 732-745.	4.1	35
42	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
43	Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28028.	1.5	33
44	NF- κ B upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. <i>Neuro-Oncology</i> , 2017, 19, 1350-1360.	1.2	32
45	Polo-like Kinase-1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. <i>BMC Cancer</i> , 2016, 16, 647.	2.6	31
46	BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. <i>Oncogene</i> , 2020, 39, 2305-2327.	5.9	31
47	Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. <i>Nature Communications</i> , 2021, 12, 5531.	12.8	31
48	Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1158.	2.4	30
49	Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma. <i>Cell Reports</i> , 2020, 31, 107485.	6.4	27
50	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 944-954.	1.2	25
51	Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells. <i>Cell Death and Disease</i> , 2019, 10, 679.	6.3	24
52	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
53	MPS1 kinase as a potential therapeutic target in medulloblastoma. <i>Oncology Reports</i> , 2016, 36, 2633-2640.	2.6	23
54	The long noncoding RNA <i>lnc-HLX-2-7</i> is oncogenic in Group 3 medulloblastomas. <i>Neuro-Oncology</i> , 2021, 23, 572-585.	1.2	23

#	ARTICLE	IF	CITATIONS
55	Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma. <i>JCI Insight</i> , 2019, 4, .	5.0	20
56	Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. <i>Oncology Reports</i> , 2018, 39, 455-464.	2.6	19
57	Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 595-604.	1.7	19
58	Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1984-1994.	4.1	19
59	Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. <i>Cell Reports</i> , 2021, 35, 109013.	6.4	18
60	Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. <i>Oncotarget</i> , 2016, 7, 53881-53894.	1.8	17
61	Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma. <i>Cancer Cell International</i> , 2017, 17, 41.	4.1	16
62	Aberrant T-Cell Antigen Receptor-Mediated Responses in Autoimmune Lymphoproliferative Syndrome. <i>Clinical Immunology</i> , 2002, 104, 31-39.	3.2	15
63	Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor. <i>Oncotarget</i> , 2017, 8, 97290-97303.	1.8	15
64	A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. <i>Neuro-Oncology</i> , 2022, 24, 414-426.	1.2	15
65	Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF- κ B Pathway in Preclinical Models of Pediatric High-Grade Glioma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 540-551.	4.1	14
66	Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 296.	2.8	14
67	Cryptic developmental events determine medulloblastoma radiosensitivity and cellular heterogeneity without altering transcriptomic profile. <i>Communications Biology</i> , 2021, 4, 616.	4.4	13
68	Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors. <i>Pediatric Blood and Cancer</i> , 2014, 61, 120-127.	1.5	12
69	Tumor treating fields in pediatric high-grade glioma. <i>Child's Nervous System</i> , 2017, 33, 1043-1045.	1.1	12
70	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 800-813.	5.6	12
71	Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 1540-1551.	1.2	11
72	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. <i>Cancer Medicine</i> , 2020, 9, 447-459.	2.8	11

#	ARTICLE	IF	CITATIONS
73	A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma. <i>Cancers</i> , 2021, 13, 387.	3.7	11
74	Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa021.	0.7	10
75	Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. <i>Journal of Neuro-Oncology</i> , 2020, 147, 531-545.	2.9	10
76	Bromodomain and extra-terminal inhibitors: A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children: ACCELERATE. <i>European Journal of Cancer</i> , 2021, 146, 115-124.	2.8	10
77	The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme. <i>Molecular Carcinogenesis</i> , 2020, 59, 1064-1075.	2.7	9
78	Therapeutic targeting of immune checkpoints with small molecule inhibitors. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 529-541.	0.0	9
79	Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels. <i>Blood</i> , 2022, 139, 2240-2251.	1.4	9
80	Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa051.	0.7	8
81	Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26656.	1.5	7
82	Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa103.	0.7	6
83	Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth. <i>Clinical Cancer Research</i> , 2022, 28, 2409-2424.	7.0	6
84	NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 345-353.	1.7	5
85	SMYD3 Promotes Cell Cycle Progression by Inducing Cyclin D3 Transcription and Stabilizing the Cyclin D1 Protein in Medulloblastoma. <i>Cancers</i> , 2022, 14, 1673.	3.7	5
86	Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	4
87	THE ROLE OF WEE1 IN Myc-DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii113.2-iii113.	1.2	2
88	SYNTHETIC LETHAL EPIGENETIC INTERACTIONS IN K27M MUTATED DIPG. <i>Neuro-Oncology</i> , 2016, 18, iii66.3-iii66.	1.2	1
89	Vincristine and Vinblastine: Is checking bilirubin mandatory in children with Brain Tumors?. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26329.	1.5	1
90	PHRM-02. DELIVERY OF CHEMOTHERAPEUTICS TO PEDIATRIC BRAIN TUMORS USING CITRATE-CAPPED GOLD NANOPARTICLES. <i>Neuro-Oncology</i> , 2018, 20, i157-i157.	1.2	1

#	ARTICLE	IF	CITATIONS
91	MEDU-13. FUNCTIONAL CRISPR-CAS9 SCREEN IDENTIFIES DRUGGABLE DEPENDENCIES IN MYC-DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii105-ii106.	1.2	1
92	Converging evidence for inhibition of transcriptional control in high-grade gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1225-1227.	1.2	1
93	Epigenetic Regulation of Von Willebrand Factor Gene Expression May Contribute to Von Willebrand Disease Severity. <i>Blood</i> , 2014, 124, 470-470.	1.4	1
94	EP-04 * ACTIVATION OF THE IL6/STAT3 PATHWAY IN CHILDHOOD EPENDYMOMA IS ASSOCIATED WITH A PRO-INFLAMMATORY TUMOR MICROENVIRONMENT AND A POOR PROGNOSIS. <i>Neuro-Oncology</i> , 2015, 17, iii6-iii6.	1.2	0
95	AT-07PLK1 AS A THERAPEUTIC TARGET IN ATRT. <i>Neuro-Oncology</i> , 2016, 18, iii2.2-iii2.	1.2	0
96	EPEN-21. SINGLE CELL RNASEQ IDENTIFIES A PUTATIVE CANCER STEM CELL POPULATION IN POSTERIOR FOSSA EPN. <i>Neuro-Oncology</i> , 2018, 20, i77-i77.	1.2	0
97	DIPG-66. THE H3K27M MUTATION CAUSES WIDE-RANGING CHANGES MEDIATING DIPG TUMORIGENESIS. <i>Neuro-Oncology</i> , 2018, 20, i62-i62.	1.2	0
98	DIPG-77. INTRATUMORAL PHARMACOKINETICS OF CHEMOTHERAPY IN DIPG: XENOGRAFT AND INITIAL PHASE 0 CLINICAL TRIAL RESULTS. <i>Neuro-Oncology</i> , 2018, 20, i64-i65.	1.2	0
99	QOL-58. IMPROVEMENT IN VISUAL ACUITY OF PEDIATRIC PATIENTS WITH BRAIN TUMORS WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2018, 20, i169-i169.	1.2	0
100	ATRT-18. VALIDATION OF PROTEASOME INHIBITION AS A THERAPEUTIC TARGET IN ATYPICAL TERATOID/RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i31-i31.	1.2	0
101	MBRS-23. EFFECT OF KNOCKDOWN OF KDM6A BY CRISPR/CAS9 EDITING IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i133-i133.	1.2	0
102	EPEN-16. PATIENT-DERIVED PFA EPENDYMOMA XENOGRAFT MODEL. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	1.2	0
103	DIPG-10. THE ONCOGENIC ROLE OF THE SUPER ELONGATION COMPLEX IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i50-i50.	1.2	0
104	HGG-45. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF PEDIATRIC TREATMENT-INDUCED HIGH-GRADE GLIOMA: GERMLINE DNA REPAIR DEFECTS AS A POTENTIAL ETIOLOGY. <i>Neuro-Oncology</i> , 2018, 20, i98-i98.	1.2	0
105	PDTM-41. SUPER ELONGATION COMPLEX-MEDIATED TRANSCRIPTIONAL DEPENDENCY IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi212-vi212.	1.2	0
106	EPEN-14. SUBGROUP-SPECIFIC THERAPY OPTIONS FOR CHILDHOOD SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	1.2	0
107	MBRS-22. EZH2 OVEREXPRESSION INCREASES THE ONCOGENIC CHARACTER OF CEREBELLAR PROGENITORS AND ISOGRAFTS IN MICE RESULT IN TUMORS RESEMBLING GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i132-i133.	1.2	0
108	EPEN-15. RETINOIDS AS POTENTIAL CHEMOTHERAPEUTIC OPTIONS FOR POSTERIOR FOSSA EPENDYMOMA OF CHILDHOOD. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	1.2	0

#	ARTICLE	IF	CITATIONS
109	MEDU-19. EZH2-REGULATED INHIBITION OF HIPK2 SUPPRESSES TREATMENT-INDUCED APOPTOSIS IN GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii107-ii107.	1.2	0
110	DIPG-07. EPIGENOME SCREENING IDENTIFIES TRANSCRIPTIONAL ELONGATION AS THERAPEUTIC VULNERABILITY IN H3K27M-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii69-ii69.	1.2	0
111	DIPG-28. NTRK FUSIONS IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, ii74-ii75.	1.2	0
112	EPEN-09. PRECLINICAL MODELS REVEAL SUBGROUP-STRATIFIED TARGETED THERAPY OPTIONS FOR CHILDHOOD SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2019, 21, ii79-ii79.	1.2	0
113	ATRT-05. PRC1 IS AN ESSENTIAL DEPENDENCY AND THERAPEUTIC TARGET IN SMARCB1 DEFICIENT ATYPICAL TERATOID RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2019, 21, ii63-ii64.	1.2	0
114	EMBR-27. NEOPLASTIC AND IMMUNE SINGLE CELL TRANSCRIPTOMICS DEFINE SUBGROUP-SPECIFIC INTRA-TUMORAL HETEROGENEITY OF CHILDHOOD MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, i11-i12.	1.2	0
115	RARE-18. NF1-MUTATED TUMORS EXHIBIT INCREASED SENSITIVITY TO AUTOPHAGY INHIBITION ALONE AND IN COMBINATION WITH MEK INHIBITION. <i>Neuro-Oncology</i> , 2021, 23, i44-i44.	1.2	0
116	EMBR-30. A NOVEL PLK1 INHIBITOR ONVANSERTIB EFFECTIVELY SENSITIZES GROUP 3 MEDULLOBLASTOMA TO RADIOTHERAPY. <i>Neuro-Oncology</i> , 2021, 23, i12-i12.	1.2	0
117	HGG-25. PRMT5 PROMOTES TUMOR GROWTH BY MAINTAINING STEMNESS OF PEDIATRIC HIGH-GRADE GLIOMA CELLS. <i>Neuro-Oncology</i> , 2021, 23, i22-i22.	1.2	0
118	HGG-29. VENETOCLAX SYNERGIZES WITH RADIATION THERAPY FOR THE TREATMENT OF DIPG. <i>Neuro-Oncology</i> , 2021, 23, i23-i23.	1.2	0
119	Successful Unrelated Umbilical Cord Blood Transplantation for Shwachman-Diamond Syndrome.. <i>Blood</i> , 2004, 104, 5179-5179.	1.4	0
120	MBRS-26. CDK7 MEDIATED TRANSCRIPTIONAL PROCESSIVITY OF DNA REPAIR NETWORKS REGULATES SENSITIVITY TO RADIATION IN MYC DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii403-iii403.	1.2	0
121	MBRS-46. CHARTING NEOPLASTIC AND IMMUNE CELL HETEROGENEITY IN HUMAN AND GEM MODELS OF MEDULLOBLASTOMA USING scRNAseq. <i>Neuro-Oncology</i> , 2020, 22, iii406-iii406.	1.2	0
122	ATRT-24. CELL SURFACE PROTEOME ANALYSIS OF ATRT IDENTIFIES TARGETS FOR IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii280-iii280.	1.2	0
123	ATRT-20. CDK7 INHIBITION IN AT/RT. <i>Neuro-Oncology</i> , 2020, 22, iii279-iii280.	1.2	0
124	EPEN-31. SINGLE-CELL RNAseq OF CHILDHOOD EPENDYMOMA REVEALS DISTINCT NEOPLASTIC CELL SUBPOPULATIONS THAT IMPACT ETIOLOGY, MOLECULAR CLASSIFICATION AND OUTCOME. <i>Neuro-Oncology</i> , 2020, 22, iii314-iii314.	1.2	0
125	IMG-17. RADIOMICS CHARACTERIZATION OF FOUR PEDIATRIC BRAIN TUMOR SUBTYPES IN PDX MOUSE MODELS. <i>Neuro-Oncology</i> , 2020, 22, iii358-iii358.	1.2	0
126	MBRS-65. FBXW7 ACTS A TUMOR SUPPRESSOR IN MYC-DRIVEN MEDULLOBLASTOMA BY CONTROLLING A FEED-FORWARD REGULATORY LOOP OF PLK1 AND MYC. <i>Neuro-Oncology</i> , 2020, 22, iii409-iii409.	1.2	0

#	ARTICLE	IF	CITATIONS
127	ATRT-06. SMARCB1 LOSS DRIVEN NON-CANONICAL PRC1 ACTIVITY REGULATES DIFFERENTIATION IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT). <i>Neuro-Oncology</i> , 2020, 22, iii276-iii277.	1.2	0
128	ATRT-23. SIRT2 cooperates with SMARCB1 to induce a differentiation block in ATRT. <i>Neuro-Oncology</i> , 2022, 24, i8-i8.	1.2	0
129	HGG-20. PRMT5 promotes the formation and growth of pediatric high-grade glioma by maintaining tumor stem cell populations. <i>Neuro-Oncology</i> , 2022, 24, i64-i65.	1.2	0
130	DIPG-56. Development and application of a novel antibody against CD99 as a therapeutic strategy in Diffuse Midline Glioma. <i>Neuro-Oncology</i> , 2022, 24, i31-i31.	1.2	0
131	MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i125-i125.	1.2	0
132	IMMU-23. Novel gene-edited CAR-T cell therapy against Diffuse Intrinsic Pontine Glioma. <i>Neuro-Oncology</i> , 2022, 24, i86-i87.	1.2	0
133	RONC-05. Peri-transplant Radiation Therapy for Young Children Treated with High-Dose Chemotherapy for Primary Brain Tumors. <i>Neuro-Oncology</i> , 2022, 24, i177-i177.	1.2	0
134	MEDB-70. Metabolism mediated radiation resistance in MYC-driven Medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i122-i123.	1.2	0
135	IMMU-21. Targeting the adenosinergic immune suppression pathway in high grade glioma synergizes with innate immune checkpoint blockade. <i>Neuro-Oncology</i> , 2022, 24, i86-i86.	1.2	0
136	ATRT-10. Single-cell transcriptional profiling of ATRTs reveals heterogeneous signatures of tumor and non-malignant cell populations. <i>Neuro-Oncology</i> , 2022, 24, i4-i5.	1.2	0
137	MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i125-i125.	1.2	0
138	DIPG-61. Preclinical efficacy of combined radiotherapy with venetoclax treatment in targeting diffuse midline gliomas. <i>Neuro-Oncology</i> , 2022, 24, i32-i33.	1.2	0
139	MEDB-44. Transcriptomic resolution of subgroup-specific medulloblastoma architecture. <i>Neuro-Oncology</i> , 2022, 24, i115-i116.	1.2	0